<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-19562" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Ciprofloxacin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Thai</surname>
            <given-names>Tony</given-names>
          </name>
          <aff>Lower Bucks Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Salisbury</surname>
            <given-names>Blake H.</given-names>
          </name>
          <aff>MSUCHM - Ascension Providence</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zito</surname>
            <given-names>Patrick M.</given-names>
          </name>
          <aff>University of Miami; Miller School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Tony Thai declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Blake Salisbury declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Patrick Zito declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-19562.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Ciprofloxacin is an antibiotic agent in the fluoroquinolone class used to treat bacterial infections such as urinary tract infections and pneumonia. Ciprofloxacin has FDA approval to treat urinary tract infections, sexually transmitted infections (gonorrhea and chancroid), skin, bone, joint infections, prostatitis, typhoid fever, gastrointestinal infections, lower respiratory tract infections, anthrax, plague, and salmonellosis. In addition, ciprofloxacin is an appropriate treatment option in patients with mixed infections or patients with predisposing factors for Gram-negative infections. This activity covers ciprofloxacin, a broad-spectrum quinolone antibiotic that members of the interprofessional team need to review its indications, coverage, contraindications, and adverse event profile to optimally manage patients' infectious diseases.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of ciprofloxacin.</p></list-item><list-item><p>Summarize the types of infections and bacterial coverage of ciprofloxacin and where it would be effective in a target population.</p></list-item><list-item><p>Recognize the potential adverse events associated with ciprofloxacin therapy.</p></list-item><list-item><p>Review the importance of improving care coordination amongst interprofessional team members to improve outcomes for patients with an infectious disease that would respond to ciprofloxacin therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19562&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19562">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-19562.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Ciprofloxacin&#x000a0;was patented in 1983 by Bayer A.G. and approved in 1987 by the United States Food and Drug Administration (USFDA).<xref ref-type="bibr" rid="article-19562.r1">[1]</xref>&#x000a0;Ciprofloxacin is an antibiotic agent in the fluoroquinolone class used to treat bacterial infections such as urinary tract infections and pneumonia.<xref ref-type="bibr" rid="article-19562.r2">[2]</xref><xref ref-type="bibr" rid="article-19562.r3">[3]</xref><xref ref-type="bibr" rid="article-19562.r2">[2]</xref>Ciprofloxacin&#x000a0;is FDA approved&#x000a0;for the treatment of urinary tract infections, sexually transmitted&#x000a0;infections (gonorrhea and chancroid, skin and soft tissue infection, bone, joint infections, prostatitis, pneumonia, typhoid fever, gastrointestinal infections, lower respiratory tract infections, inhalation anthrax (post-exposure prophylaxis), plague, and salmonellosis, acute bacterial exacerbation of chronic bronchitis.<xref ref-type="bibr" rid="article-19562.r4">[4]</xref><xref ref-type="bibr" rid="article-19562.r5">[5]</xref><xref ref-type="bibr" rid="article-19562.r6">[6]</xref><bold>&#x000a0;</bold>It should be recognized that&#x000a0;&#x000a0;<italic toggle="yes">Neisseria gonorrhea</italic>&#x000a0;has high rates of resistance to ciprofloxacin.<xref ref-type="bibr" rid="article-19562.r6">[6]</xref>&#x000a0;Ciprofloxacin should not be the first-line empirical&#x000a0;treatment for respiratory tract infections if penicillin-susceptible <italic toggle="yes">Streptococcus pneumoniae</italic> is the primary pathogen. Ciprofloxacin is an appropriate treatment option in patients with mixed infections or patients with predisposing factors for Gram-negative infections.&#x000a0;According to the American academy of family physicians guidelines, acute bacterial prostatitis can be treated with&#x000a0;ciprofloxacin.<xref ref-type="bibr" rid="article-19562.r7">[7]</xref>&#x000a0;Ciprofloxacin is also used for chronic bacterial prostatitis(which requires 4-week therapy).<xref ref-type="bibr" rid="article-19562.r8">[8]</xref>&#x000a0;&#x000a0;Ciprofloxacin is&#x000a0;used&#x000a0;off-label to treat Crohn's disease associated with perianal fistula.<xref ref-type="bibr" rid="article-19562.r9">[9]</xref></p>
        <p>Ciprofloxacin ophthalmic solution is FDA-approved for treating corneal ulcers and conjunctivitis caused by susceptible strains.<xref ref-type="bibr" rid="article-19562.r10">[10]</xref><xref ref-type="bibr" rid="article-19562.r11">[11]</xref></p>
        <p>Ciprofloxacin otic solution is approved for treating acute otitis externa caused by susceptible&#x000a0;strains of&#x000a0;<italic toggle="yes">Pseudomonas aeruginosa</italic>&#x000a0;or&#x000a0;<italic toggle="yes">Staphylococcus aureus</italic>.<xref ref-type="bibr" rid="article-19562.r12">[12]</xref>&#x000a0;Ciprofloxacin suspension gel is FDA approved for pediatric otitis media with effusion.<xref ref-type="bibr" rid="article-19562.r13">[13]</xref></p>
        <p>Ciprofloxacin does not have a marketed indication for neonates worldwide; however, it is prescribed for life-threatening infections as salvage therapy for sepsis due to multi-drug resistance (mainly in Europe and developing countries). A systematic search of observational cohort studies and case reports suggests that most clinical responses were positive, and there was a lack of serious adverse events, especially joint toxicity.<xref ref-type="bibr" rid="article-19562.r14">[14]</xref>&#x000a0;Ciprofloxacin has also attracted interest from the scientific community due to its apoptotic and antiproliferative activities in several cancer lines.<xref ref-type="bibr" rid="article-19562.r1">[1]</xref>&#x000a0;Researchers observed that it could induce dose- and time-dependent growth inhibition and apoptosis of various carcinoma, osteosarcoma, and leukemia cell lines.<xref ref-type="bibr" rid="article-19562.r15">[15]</xref>&#x000a0;Ciprofloxacin also has potential benefits in bladder cancer management.&#x000a0;<italic toggle="yes">In vitro</italic>&#x000a0;studies&#x000a0;on&#x000a0;tumor&#x000a0;cells&#x000a0;made&#x000a0;from transitional cell&#x000a0;carcinoma&#x000a0;of&#x000a0;the&#x000a0;bladder resulted in both a dose and time-dependent inhibition of cell growth. These results were achieved by ciprofloxacin with concentrations that are easily attainable in the urine of patients. However, these indications require additional clinical research.<xref ref-type="bibr" rid="article-19562.r16">[16]</xref></p>
      </sec>
      <sec id="article-19562.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Ciprofloxacin is a bactericidal antibiotic of the fluoroquinolone drug class. It inhibits DNA replication by inhibiting bacterial DNA topoisomerase and DNA-gyrase. Of the fluoroquinolone class, ciprofloxacin is the most potent against gram-negative bacilli bacteria (notably, the <italic toggle="yes">Enterobacteriaceae</italic> such as <italic toggle="yes">Escherichia coli</italic>, <italic toggle="yes">Salmonella</italic> spp., <italic toggle="yes">Shigella</italic> spp., and <italic toggle="yes">Neisseria</italic>).<xref ref-type="bibr" rid="article-19562.r17">[17]</xref> Ciprofloxacin also has effectiveness against some gram-positive bacteria. Ciprofloxacin is the most active against <italic toggle="yes">Pseudomonas aeruginosa&#x000a0;</italic>among the quinolones.<xref ref-type="bibr" rid="article-19562.r18">[18]</xref> Progressively decreasing susceptibility among <italic toggle="yes">P. aeruginosa </italic>has been reported in Europe, North and South America, predominantly in the hospital or nursing home settings with identifiable risk factors. Ciprofloxacin is one of the few oral antibiotics to treat <italic toggle="yes">P. aeruginosa&#x000a0;</italic>infections.<xref ref-type="bibr" rid="article-19562.r19">[19]</xref></p>
        <p><bold>Mechanism of Resistance:&#x000a0; </bold>Mutation in DNA gyrase, plasmid-mediated and efflux pump-mediated resistance confers resistance to fluoroquinolones, including&#x000a0;ciprofloxacin. For&#x000a0;<italic toggle="yes">Escherichia coli</italic>, the primary resistance mechanism is generally the GyrA subunit of gyrase.<xref ref-type="bibr" rid="article-19562.r20">[20]</xref><xref ref-type="bibr" rid="article-19562.r21">[21]</xref>&#x000a0;Ciprofloxacin can be less costly and more cost-effective than traditional parenteral regimens in selected clinical settings with appropriate use. Additional well-designed studies would be helpful in further defining the most cost-efficient use of this antimicrobial agent. However, in&#x000a0;<italic toggle="yes">E. coli</italic>-associated urinary tract infections, there has been an increase in ciprofloxacin resistance, more so in the hospital versus the community setting.<xref ref-type="bibr" rid="article-19562.r22">[22]</xref>&#x000a0;Evaluation of the use of ciprofloxacin as empiric therapy should be on a case-by-case basis.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption: </bold>Ciprofloxacin is readily absorbed but typically does not achieve complete absorption. The bioavailability of oral ciprofloxacin is 70 to 80%. The time to peak concentrations after oral administration Tmax is 1&#x000a0;to 1.5 h.<xref ref-type="bibr" rid="article-19562.r18">[18]</xref>&#x000a0;&#x000a0;Avoid concurrent administration of ciprofloxacin with dairy products or calcium-fortified juices due to decreased absorption.<xref ref-type="bibr" rid="article-19562.r23">[23]</xref></p>
        <p><bold>Distribution: </bold>The volume of distribution of ciprofloxacin is high (2&#x000a0;to 3 L/kg). After oral administration, ciprofloxacin is extensively distributed throughout the body. Tissue concentrations usually exceed serum concentrations, and ciprofloxacin achieves therapeutic concentrations in saliva, bronchial secretions, lymph, bile, the prostate, and urine.<xref ref-type="bibr" rid="article-19562.r24">[24]</xref><xref ref-type="bibr" rid="article-19562.r25">[25]</xref><xref ref-type="bibr" rid="article-19562.r26">[26]</xref>&#x000a0;Cerebrospinal fluid concentrations are usually lower than plasma concentration, but CSF concentration increases during active meningeal inflammation.<xref ref-type="bibr" rid="article-19562.r27">[27]</xref>&#x000a0;Topically applied ciprofloxacin is also present in the aqueous humor of the eye.<xref ref-type="bibr" rid="article-19562.r28">[28]</xref></p>
        <p><bold>Metabolism: </bold>Ciprofloxacin is an inhibitor of human cytochrome P450 1A2 (CYP1A2). Co-administration of ciprofloxacin with other drugs metabolized by CYP1A2 results in increased plasma concentrations of these drugs and could lead to toxicity.<xref ref-type="bibr" rid="article-19562.r29">[29]</xref></p>
        <p><bold>Excretion: </bold>The elimination half-life of ciprofloxacin is 4 hours. Ciprofloxacin is excreted in the urine as an unchanged drug (40 to 50%). The renal clearance of ciprofloxacin is approximately 300 mL/minute, which is greater than the normal GFR of 120 mL/minute; thus, tubular secretion is the dominant process in the renal elimination of ciprofloxacin. Approximately 20% to 35% of an oral dose is recovered from feces. Biliary clearance and transintestinal elimination play a significant role in excretion through feces.<xref ref-type="bibr" rid="article-19562.r30">[30]</xref></p>
      </sec>
      <sec id="article-19562.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Ciprofloxacin is available orally, intravenously, and in topical formulations (ophthalmic and otic).</p>
        <p>Ciprofloxacin&#x000a0;is administered&#x000a0;orally twice daily for 7 to 14 days or at least two days after signs and symptoms of the infection are over. The recommended oral dose regimen is 250 mg twice daily to treat mild to moderate and 500 mg twice daily for severe or complicated urinary tract infections. Therapy for mild to moderate respiratory tract or skin and soft-tissue infections require 500mg twice-daily dosing. Comparatively, a dosage of 750mg twice daily is recommended&#x000a0;for severe or complicated infections. Ciprofloxacin should be given with food to minimize gastrointestinal upset.&#x000a0;</p>
        <p>An intravenous dosage of 200 to 400 mg twice daily is recommended&#x000a0;for mild-to-moderate infections and up to 400 mg every 8 hours for severe, life-threatening infections.<xref ref-type="bibr" rid="article-19562.r31">[31]</xref>&#x000a0;The recommendation is a 50% reduction in daily dosage for patients with severe renal impairment (creatinine clearance = 1.2 L/hour). Ciprofloxacin is administered&#x000a0;intravenously by slow infusion over 60 minutes. It is essential to maintain proper hydration and urine output. Usage of&#x000a0;antacids should&#x000a0;be avoided, or at least administer ciprofloxacin either two hours before or six hours after antacids for both the immediate or the extended-release formulations. The oral suspension should not&#x000a0;be administered&#x000a0;through feeding tubes as the suspension may adhere to the tube. Otic ciprofloxacin is a safe and effective antibiotic used in treating chronic otitis media compared to ciprofloxacin tablets.<xref ref-type="bibr" rid="article-19562.r32">[32]</xref></p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Patients with Hepatic Impairment:&#x000a0;</bold> In patients with liver cirrhosis, no significant changes in the pharmacokinetics of ciprofloxacin have been observed. However, ciprofloxacin's pharmacokinetics are not fully studied in patients with acute hepatic insufficiency. Additionally, ciprofloxacin has the potential to cause hepatotoxicity. Use with caution in patients with impaired hepatic function.<xref ref-type="bibr" rid="article-19562.r33">[33]</xref>&#x000a0;</p>
        <p><bold>Patients with Renal Impairment: </bold>As discussed in pharmacokinetics, ciprofloxacin is primarily eliminated by the renal route; dosage adjustment is required, especially in severe renal impairment.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>No dose adjustment is required for creatinine clearance &#x0003e; 50 mL/min/1.73m^2.</p>
          </list-item>
          <list-item>
            <p>For creatinine clearance between 30-49 mL/min/1.73m^2, 250&#x02013;500 mg every 12 hours is recommended.</p>
          </list-item>
          <list-item>
            <p>For creatinine clearance between 5&#x02013;29 mL/min/1.73m^2,&#x000a0; 250&#x02013;500 mg every 18 hours is recommended.</p>
          </list-item>
          <list-item>
            <p>For patients on hemodialysis or peritoneal dialysis, 250&#x02013;500 mg every 24 hours (after dialysis).</p>
          </list-item>
          <list-item>
            <p>For patients on&#x000a0;CRRT having sepsis, 200 to 400 mg every 8 to 12 hours is recommended.<xref ref-type="bibr" rid="article-19562.r34">[34]</xref></p>
          </list-item>
        </list>
        <p><bold>Pregnancy Considerations:&#x000a0;</bold>Conventionally, ciprofloxacin and other fluoroquinolones are contraindicated during pregnancy due to bone and cartilage damage concerns. However, available clinical data haven't&#x000a0;identified any drug-associated risk of major congenital disabilities, adverse&#x000a0;pregnancy-associated outcomes or miscarriage, or adverse&#x000a0;pregnancy-associated outcomes.<xref ref-type="bibr" rid="article-19562.r35">[35]</xref><xref ref-type="bibr" rid="article-19562.r36">[36]</xref>&#x000a0;Hence, the recommendation is to allow fluoroquinolone(including ciprofloxacin) use in early pregnancy in antimicrobial resistance or intolerance to the first-line antibiotics. Use ciprofloxacin only for compelling indications like inhalation anthrax. Similarly, reserve ciprofloxacin for severe Crohn's disease with the perianal disease; otherwise, the use of amoxicillin-metronidazole is recommended. (American gastroenterological association guidelines).<xref ref-type="bibr" rid="article-19562.r37">[37]</xref></p>
        <p><bold>Breastfeeding Considerations: </bold>Ciprofloxacin has&#x000a0;conventionally&#x000a0;not been&#x000a0;recommended in nursing mothers because of concern regarding adverse effects on the developing joints. The calcium in milk might decrease the absorption of the small amounts of fluoroquinolones in milk, but&#x000a0;clinical data is inadequate to support this assumption. The use of ciprofloxacin is&#x000a0;justified in nursing mothers for&#x000a0;required indications with monitoring of the infant for adverse drug reactions such as diarrhea or candidiasis. A possible strategy to avoid an infant's exposure to ciprofloxacin in breast milk is avoiding breastfeeding for 3 to 4 hours after the last dose of ciprofloxacin.<xref ref-type="bibr" rid="article-19562.r38">[38]</xref></p>
      </sec>
      <sec id="article-19562.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Adverse effects are mild at therapeutic doses and are mostly limited to gastrointestinal disruptions such as nausea and diarrhea. The serious adverse effects of ciprofloxacin include prolonged&#x000a0;QT&#x000a0;interval, hyper or hypoglycemia, and photosensitivity.<xref ref-type="bibr" rid="article-19562.r39">[39]</xref>&#x000a0;&#x000a0;Rare interactions include drug-induced bullous pemphigoid.<xref ref-type="bibr" rid="article-19562.r40">[40]</xref></p>
        <p>FDA&#x000a0; boxed warnings include tendinitis and tendon rupture, peripheral neuropathy and neuropsychiatric adverse events,&#x000a0;and exacerbation of myasthenia gravis. The most common type of tendon rupture involves the Achilles tendon. There have also been reports of tendinopathies in the gluteal, iliopsoas, and triceps tendons<bold>. </bold>The use of steroids and advanced age increased the risk of tendonitis. Upregulation of matrix metalloproteinases leading to collagen degradation is a possible mechanism for tendinopathy.<xref ref-type="bibr" rid="article-19562.r41">[41]</xref><xref ref-type="bibr" rid="article-19562.r42">[42]</xref><xref ref-type="bibr" rid="article-19562.r43">[43]</xref>&#x000a0;Oral fluoroquinolone therapy, including ciprofloxacin, is associated with an increased risk of peripheral neuropathy based on the cumulative dose.&#x000a0;Evidence of small fiber&#x000a0;damage can be detected in&#x000a0;nerve biopsy.<xref ref-type="bibr" rid="article-19562.r44">[44]</xref>&#x000a0;Neuropsychiatric adverse events include&#x000a0;agitation, tremors, hallucinations, psychosis, and seizures.<xref ref-type="bibr" rid="article-19562.r45">[45]</xref></p>
        <p>Aortic aneurysm and aortic dissection have been associated with the use of fluoroquinolones.&#x000a0;Prolonged&#x000a0;fluoroquinolone therapy and older age are the associated risk factors. Discontinue ciprofloxacin immediately if there is a suspicion of aortic dissection.<xref ref-type="bibr" rid="article-19562.r46">[46]</xref></p>
      </sec>
      <sec id="article-19562.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Contraindications to ciprofloxacin include patients with documented hypersensitivity to the drug or components of the formulation. Anaphylactoid reactions and anaphylaxis following the first dose of ciprofloxacin have been reported in the literature.<xref ref-type="bibr" rid="article-19562.r47">[47]</xref><xref ref-type="bibr" rid="article-19562.r48">[48]</xref>&#x000a0;The concurrent administration of&#x000a0;tizanidine for muscle spasms is also a contraindication.&#x000a0;The pharmacokinetics of tizanidine are altered by CYP1A2 inhibition (ciprofloxacin), leading to increased&#x000a0;tizanidine levels and decreased psychomotor activity, blood pressure, and heart rate.<xref ref-type="bibr" rid="article-19562.r31">[31]</xref><xref ref-type="bibr" rid="article-19562.r49">[49]</xref> Avoid ciprofloxacin and its fluoroquinolone class in patients with myasthenia gravis because it may exacerbate muscle weaknesses.</p>
      </sec>
      <sec id="article-19562.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Providers should monitor patients taking ciprofloxacin for symptoms of tendinitis, altered mental status, complete blood count, and renal and hepatic function in prolonged therapy. Other significant interactions with ciprofloxacin include theophylline (particularly concurrent caffeine use), which acts on the CYP1A2 and raises theophylline levels.<xref ref-type="bibr" rid="article-19562.r31">[31]</xref>&#x000a0;Reports have shown that using ciprofloxacin can lead to elevated cyclosporine serum levels. Oral absorption of ciprofloxacin decreases with antacids containing agents such as aluminum and magnesium.&#x000a0;Monitor patients for&#x000a0;g&#x000a0;<italic toggle="yes">Clostridioides difficile-associated</italic>&#x000a0;diarrhea.<xref ref-type="bibr" rid="article-19562.r50">[50]</xref>&#x000a0;Monitor serum glucose levels, especially in patients with diabetes, on insulin therapy as dysglycemia is a known adverse reaction of fluoroquinolones, including ciprofloxacin.<xref ref-type="bibr" rid="article-19562.r47">[47]</xref><xref ref-type="bibr" rid="article-19562.r51">[51]</xref><xref ref-type="bibr" rid="article-19562.r52">[52]</xref></p>
      </sec>
      <sec id="article-19562.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>The elimination half-life of ciprofloxacin ranges from 3.3 to 6.8 hours in the elderly compared with three to four hours in younger persons.<xref ref-type="bibr" rid="article-19562.r53">[53]</xref> There is limited evidence suggesting ciprofloxacin excretion in breast milk.<xref ref-type="bibr" rid="article-19562.r54">[54]</xref>. Clinical data indicate no significant evidence of osteoarticular toxicity in newborns and children. In these studies, the drug exposure of neonates and children was at much higher doses compared to children whose exposure was via breastfeeding.<xref ref-type="bibr" rid="article-19562.r14">[14]</xref>&#x000a0;</p>
        <p>Acute kidney injury following ciprofloxacin overdose has been reported. There is no specific antidote to ciprofloxacin overdose.&#x000a0;Consider using magnesium and calcium-containing antacids to reduce the oral absorption of ciprofloxacin. Consider intermittent hemodialysis for ciprofloxacin-induced&#x000a0;nephrotoxicity.<xref ref-type="bibr" rid="article-19562.r55">[55]</xref><xref ref-type="bibr" rid="article-19562.r56">[56]</xref></p>
      </sec>
      <sec id="article-19562.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Ciprofloxacin can be less costly and more cost-effective than traditional parenteral regimens in selected clinical settings with appropriate use. Additional well-designed studies would be helpful in further defining the most cost-efficient use of this antimicrobial agent. However, in&#x000a0;<italic toggle="yes">E. coli</italic>-associated urinary tract infections, there has been an increase in ciprofloxacin resistance, more so in the hospital versus the community setting.<xref ref-type="bibr" rid="article-19562.r22">[22]</xref>&#x000a0;Evaluation of the use of ciprofloxacin as empiric therapy should be on a case-by-case basis.</p>
        <p>Ciprofloxacin is a common antibiotic prescribed and usually well-tolerated. Interprofessional health care team members must&#x000a0;use antibiotics as targeted therapy, effectively managing infections and conferring a societal benefit in addressing drug-resistant microbes. Clinicians need to consider that the drug's pharmacokinetics can undergo alteration in patients with renal or hepatic dysfunction and order the tests to monitor patient status when used for a prolonged period.&#x000a0;Pharmacists can review the antibiogram and verify the dosing and duration of ciprofloxacin. Nursing can counsel the patient on taking the medication, monitor patient compliance and therapeutic effectiveness, answer any questions, and report any concerns to the prescriber. Ciprofloxacin therapy requires the collaborative approach of an interprofessional healthcare team, including infectious disease specialists, clinicians (MD, DO, NP, PA), pharmacists, and specialty-trained nurses working together to achieve optimal patient outcomes. All team members must be vigilant for adverse events or therapeutic failure and immediately report any patient status changes to other team members. A study shows that hospital-based antimicrobial stewardship interventions are associated with fewer&#x000a0;fluoroquinolone (including ciprofloxacin)&#x000a0;prescriptions during hospitalization.<xref ref-type="bibr" rid="article-19562.r57">[57]</xref>&#x000a0;[Level 3]</p>
      </sec>
      <sec id="article-19562.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19562&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19562">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/19562/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=19562">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-19562.s11">
        <title>References</title>
        <ref id="article-19562.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pahwa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Yar</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Ciprofloxacin: review on developments in synthetic, analytical, and medicinal aspects.</article-title>
            <source>J Enzyme Inhib Med Chem</source>
            <year>2010</year>
            <month>Aug</month>
            <volume>25</volume>
            <issue>4</issue>
            <fpage>577</fpage>
            <page-range>577-89</page-range>
            <pub-id pub-id-type="pmid">20235755</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Qiu</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Tao</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>Antibiotics for treatment of acute exacerbation of chronic obstructive pulmonary disease: a network meta-analysis.</article-title>
            <source>BMC Pulm Med</source>
            <year>2017</year>
            <month>Dec</month>
            <day>12</day>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>196</fpage>
            <pub-id pub-id-type="pmid">29233130</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bartolom&#x000e9;-&#x000c1;lvarez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Solves-Ferriz</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>[Increase in methicillin-resistant and ciprofloxacin-susceptible Staphylococcus aureus in osteoarticular, skin and soft tissue infections].</article-title>
            <source>Rev Esp Quimioter</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>33</volume>
            <issue>2</issue>
            <fpage>143</fpage>
            <page-range>143-144</page-range>
            <pub-id pub-id-type="pmid">32157857</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meyerhoff</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Albrecht</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Dionne</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Higgins</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>US Food and Drug Administration approval of ciprofloxacin hydrochloride for management of postexposure inhalational anthrax.</article-title>
            <source>Clin Infect Dis</source>
            <year>2004</year>
            <month>Aug</month>
            <day>01</day>
            <volume>39</volume>
            <issue>3</issue>
            <fpage>303</fpage>
            <page-range>303-8</page-range>
            <pub-id pub-id-type="pmid">15306995</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Apangu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Griffith</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Abaru</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Candini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Apio</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Okoth</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Okello</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kaggwa</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Acayo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ezama</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Yockey</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sexton</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schriefer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mbidde</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Mead</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Successful Treatment of Human Plague with Oral Ciprofloxacin.</article-title>
            <source>Emerg Infect Dis</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>553</fpage>
            <page-range>553-5</page-range>
            <pub-id pub-id-type="pmid">28125398</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Unemo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lahra</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Cole</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Galarza</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ndowa</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Dillon</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Ramon-Pardo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bolan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wi</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>World Health Organization Global Gonococcal Antimicrobial Surveillance Program (WHO GASP): review of new data and evidence to inform international collaborative actions and research efforts.</article-title>
            <source>Sex Health</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>16</volume>
            <issue>5</issue>
            <fpage>412</fpage>
            <page-range>412-425</page-range>
            <pub-id pub-id-type="pmid">31437420</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coker</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Dierfeldt</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Acute Bacterial Prostatitis: Diagnosis and Management.</article-title>
            <source>Am Fam Physician</source>
            <year>2016</year>
            <month>Jan</month>
            <day>15</day>
            <volume>93</volume>
            <issue>2</issue>
            <fpage>114</fpage>
            <page-range>114-20</page-range>
            <pub-id pub-id-type="pmid">26926407</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heras-Ca&#x000f1;as</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Guti&#x000e9;rrez-Soto</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Almonte-Fern&#x000e1;ndez</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lara-Oya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Navarro-Mar&#x000ed;</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Garrido-Frenich</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>V&#x000e1;zquez-Alonso</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Guti&#x000e9;rrez-Fern&#x000e1;ndez</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Antibiotic activity and concentrations in clinical samples from patients with chronic bacterial prostatitis.</article-title>
            <source>Actas Urol Esp</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>41</volume>
            <issue>10</issue>
            <fpage>631</fpage>
            <page-range>631-638</page-range>
            <pub-id pub-id-type="pmid">28641870</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>XW</given-names>
              </name>
              <name>
                <surname>Ji</surname>
                <given-names>HZ</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>FY</given-names>
              </name>
            </person-group>
            <article-title>Meta-analysis of ciprofloxacin in treatment of Crohn's disease.</article-title>
            <source>Biomed Rep</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>70</fpage>
            <page-range>70-74</page-range>
            <pub-id pub-id-type="pmid">25469250</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McDonald</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Ram</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>McGhee</surname>
                <given-names>CN</given-names>
              </name>
            </person-group>
            <article-title>Topical antibiotics for the management of bacterial keratitis: an evidence-based review of high quality randomised controlled trials.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>98</volume>
            <issue>11</issue>
            <fpage>1470</fpage>
            <page-range>1470-7</page-range>
            <pub-id pub-id-type="pmid">24729078</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mohamed</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Elmohamady</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Abdelrahman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Amer</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Abdelhamid</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Antibacterial effects of antibiotics and cell-free preparations of probiotics against <italic>Staphylococcus aureus</italic> and <italic>Staphylococcus epidermidis</italic> associated with conjunctivitis.</article-title>
            <source>Saudi Pharm J</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>28</volume>
            <issue>12</issue>
            <fpage>1558</fpage>
            <page-range>1558-1565</page-range>
            <pub-id pub-id-type="pmid">33424249</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wiegand</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Berner</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lundershausen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dietz</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Otitis Externa.</article-title>
            <source>Dtsch Arztebl Int</source>
            <year>2019</year>
            <month>Mar</month>
            <day>29</day>
            <volume>116</volume>
            <issue>13</issue>
            <fpage>224</fpage>
            <page-range>224-234</page-range>
            <pub-id pub-id-type="pmid">31064650</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Edmunds</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>Otiprio: An FDA-Approved Ciprofloxacin Suspension Gel for Pediatric Otitis Media With Effusion.</article-title>
            <source>P T</source>
            <year>2017</year>
            <month>May</month>
            <volume>42</volume>
            <issue>5</issue>
            <fpage>307</fpage>
            <page-range>307-311</page-range>
            <pub-id pub-id-type="pmid">28479839</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaguelidou</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Choonara</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Jacqz-Aigrain</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Ciprofloxacin use in neonates: a systematic review of the literature.</article-title>
            <source>Pediatr Infect Dis J</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>e29</fpage>
            <page-range>e29-37</page-range>
            <pub-id pub-id-type="pmid">21048525</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Herold</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ocker</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ganslmayer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gerauer</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hahn</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Schuppan</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Ciprofloxacin induces apoptosis and inhibits proliferation of human colorectal carcinoma cells.</article-title>
            <source>Br J Cancer</source>
            <year>2002</year>
            <month>Feb</month>
            <day>01</day>
            <volume>86</volume>
            <issue>3</issue>
            <fpage>443</fpage>
            <page-range>443-8</page-range>
            <pub-id pub-id-type="pmid">11875713</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aranha</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Sarkar</surname>
                <given-names>FH</given-names>
              </name>
            </person-group>
            <article-title>Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line.</article-title>
            <source>Clin Cancer Res</source>
            <year>2000</year>
            <month>Mar</month>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>891</fpage>
            <page-range>891-900</page-range>
            <pub-id pub-id-type="pmid">10741713</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Campoli-Richards</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Monk</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Benfield</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Todd</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.</article-title>
            <source>Drugs</source>
            <year>1988</year>
            <month>Apr</month>
            <volume>35</volume>
            <issue>4</issue>
            <fpage>373</fpage>
            <page-range>373-447</page-range>
            <pub-id pub-id-type="pmid">3292209</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>LeBel</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Ciprofloxacin: chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions.</article-title>
            <source>Pharmacotherapy</source>
            <year>1988</year>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-33</page-range>
            <pub-id pub-id-type="pmid">2836821</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rehman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Patrick</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Lamont</surname>
                <given-names>IL</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of ciprofloxacin resistance in Pseudomonas aeruginosa: new approaches to an old problem.</article-title>
            <source>J Med Microbiol</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>68</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-10</page-range>
            <pub-id pub-id-type="pmid">30605076</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>G&#x000fc;ler</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Era&#x000e7;</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>[Investigation of fluoroquinolone resistance mechanisms in clinical Acinetobacter baumannii isolates].</article-title>
            <source>Mikrobiyol Bul</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>50</volume>
            <issue>2</issue>
            <fpage>278</fpage>
            <page-range>278-86</page-range>
            <pub-id pub-id-type="pmid">27175500</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chang</surname>
                <given-names>MX</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>XL</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Webber</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>HX</given-names>
              </name>
            </person-group>
            <article-title>Contribution of Different Mechanisms to Ciprofloxacin Resistance in <italic>Salmonella</italic> spp.</article-title>
            <source>Front Microbiol</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>663731</fpage>
            <pub-id pub-id-type="pmid">34025618</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fasugba</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Gardner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Mnatzaganian</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Ciprofloxacin resistance in community- and hospital-acquired Escherichia coli urinary tract infections: a systematic review and meta-analysis of observational studies.</article-title>
            <source>BMC Infect Dis</source>
            <year>2015</year>
            <month>Nov</month>
            <day>25</day>
            <volume>15</volume>
            <fpage>545</fpage>
            <pub-id pub-id-type="pmid">26607324</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>El-Sabawi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Abu-Dahab</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zalloum</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Ijbara</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hamdan</surname>
                <given-names>II</given-names>
              </name>
            </person-group>
            <article-title>The effect of ferrous ions, calcium ions and citric acid on absorption of ciprofloxacin across caco-2 cells: practical and structural approach.</article-title>
            <source>Drug Dev Ind Pharm</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>45</volume>
            <issue>2</issue>
            <fpage>292</fpage>
            <page-range>292-303</page-range>
            <pub-id pub-id-type="pmid">30348012</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Radovanovic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dushenkovska</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cvorovic</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Radovanovic</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ramasamy</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Milosavljevic</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Surla</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jecmenica</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Radulovic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Milovanovic</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dumic</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Idiosyncratic Drug-Induced Liver Injury Due to Ciprofloxacin: A Report of Two Cases and Review of the Literature.</article-title>
            <source>Am J Case Rep</source>
            <year>2018</year>
            <month>Sep</month>
            <day>29</day>
            <volume>19</volume>
            <fpage>1152</fpage>
            <page-range>1152-1161</page-range>
            <pub-id pub-id-type="pmid">30266895</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schlender</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Teutonico</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Coboeken</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Schnizler</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Eissing</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Willmann</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jaehde</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Stass</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>A Physiologically-Based Pharmacokinetic Model to Describe Ciprofloxacin Pharmacokinetics Over the Entire Span of Life.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>57</volume>
            <issue>12</issue>
            <fpage>1613</fpage>
            <page-range>1613-1634</page-range>
            <pub-id pub-id-type="pmid">29737457</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eyler</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Shvets</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Clinical Pharmacology of Antibiotics.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2019</year>
            <month>Jul</month>
            <day>05</day>
            <volume>14</volume>
            <issue>7</issue>
            <fpage>1080</fpage>
            <page-range>1080-1090</page-range>
            <pub-id pub-id-type="pmid">30862698</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nau</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>S&#x000f6;rgel</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Eiffert</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections.</article-title>
            <source>Clin Microbiol Rev</source>
            <year>2010</year>
            <month>Oct</month>
            <volume>23</volume>
            <issue>4</issue>
            <fpage>858</fpage>
            <page-range>858-83</page-range>
            <pub-id pub-id-type="pmid">20930076</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silva</surname>
                <given-names>GCM</given-names>
              </name>
              <name>
                <surname>Jabor</surname>
                <given-names>VAP</given-names>
              </name>
              <name>
                <surname>Bonato</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>EZ</given-names>
              </name>
              <name>
                <surname>Faria-E-Sousa</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Penetration of 0.3% ciprofloxacin, 0.3% ofloxacin, and 0.5% moxifloxacin into the cornea and aqueous humor of enucleated human eyes.</article-title>
            <source>Braz J Med Biol Res</source>
            <year>2017</year>
            <month>Jul</month>
            <day>03</day>
            <volume>50</volume>
            <issue>7</issue>
            <fpage>e5901</fpage>
            <pub-id pub-id-type="pmid">28678917</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rudolph</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dahmke</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kupferschmidt</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Burden</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Weiler</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Coadministration of tizanidine and ciprofloxacin: a retrospective analysis of the WHO pharmacovigilance database.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>77</volume>
            <issue>6</issue>
            <fpage>895</fpage>
            <page-range>895-902</page-range>
            <pub-id pub-id-type="pmid">33404754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Begg</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Robson</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Saunders</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Buttimore</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Neill</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Town</surname>
                <given-names>GI</given-names>
              </name>
            </person-group>
            <article-title>The pharmacokinetics of oral fleroxacin and ciprofloxacin in plasma and sputum during acute and chronic dosing.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2000</year>
            <month>Jan</month>
            <volume>49</volume>
            <issue>1</issue>
            <fpage>32</fpage>
            <page-range>32-8</page-range>
            <pub-id pub-id-type="pmid">10606835</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davis</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Markham</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Balfour</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.</article-title>
            <source>Drugs</source>
            <year>1996</year>
            <month>Jun</month>
            <volume>51</volume>
            <issue>6</issue>
            <fpage>1019</fpage>
            <page-range>1019-74</page-range>
            <pub-id pub-id-type="pmid">8736621</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Samarei</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Comparison of local and systemic ciprofloxacin ototoxicity in the treatment of chronic media otitis.</article-title>
            <source>Glob J Health Sci</source>
            <year>2014</year>
            <month>Sep</month>
            <day>18</day>
            <volume>6</volume>
            <issue>7 Spec No</issue>
            <fpage>144</fpage>
            <page-range>144-9</page-range>
            <pub-id pub-id-type="pmid">25363170</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r33">
          <label>33</label>
          <element-citation publication-type="book">
            <chapter-title>Ciprofloxacin</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2020</year>
            <month>2</month>
            <day>28</day>
            <pub-id pub-id-type="pmid">31643397</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roger</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wallis</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Louart</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lefrant</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Lipman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Muller</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>71</volume>
            <issue>6</issue>
            <fpage>1643</fpage>
            <page-range>1643-50</page-range>
            <pub-id pub-id-type="pmid">26957490</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Padberg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wacker</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Meister</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Panse</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Weber-Schoendorfer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Oppermann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schaefer</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Observational cohort study of pregnancy outcome after first-trimester exposure to fluoroquinolones.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>58</volume>
            <issue>8</issue>
            <fpage>4392</fpage>
            <page-range>4392-8</page-range>
            <pub-id pub-id-type="pmid">24841264</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yefet</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Chazan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Salim</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Romano</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nachum</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>The safety of quinolones and fluoroquinolones in pregnancy: a meta-analysis.</article-title>
            <source>BJOG</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>125</volume>
            <issue>9</issue>
            <fpage>1069</fpage>
            <page-range>1069-1076</page-range>
            <pub-id pub-id-type="pmid">29319210</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mahadevan</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bernasko</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Boland</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chambers</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dubinsky</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kane</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Manthey</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sauberan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group.</article-title>
            <source>Gastroenterology</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>156</volume>
            <issue>5</issue>
            <fpage>1508</fpage>
            <page-range>1508-1524</page-range>
            <pub-id pub-id-type="pmid">30658060</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r38">
          <label>38</label>
          <element-citation publication-type="book">
            <chapter-title>Ciprofloxacin</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>12</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">30000643</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blondeau</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Expanded activity and utility of the new fluoroquinolones: a review.</article-title>
            <source>Clin Ther</source>
            <year>1999</year>
            <month>Jan</month>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-40; discussion 1-2</page-range>
            <pub-id pub-id-type="pmid">10090423</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cozzani</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chinazzo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Burlando</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Romagnoli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Parodi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Ciprofloxacin as a Trigger for Bullous Pemphigoid: The Second Case in the Literature.</article-title>
            <source>Am J Ther</source>
            <year>2016</year>
            <season>Sep-Oct</season>
            <volume>23</volume>
            <issue>5</issue>
            <fpage>e1202</fpage>
            <page-range>e1202-4</page-range>
            <pub-id pub-id-type="pmid">26164023</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shimatsu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Subramaniam</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sim</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Aronowitz</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Ciprofloxacin-induced tendinopathy of the gluteal tendons.</article-title>
            <source>J Gen Intern Med</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>29</volume>
            <issue>11</issue>
            <fpage>1559</fpage>
            <page-range>1559-62</page-range>
            <pub-id pub-id-type="pmid">25047394</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fackrell</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Henderson</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Ciprofloxacin-associated bilateral iliopsoas tendon rupture: a case report.</article-title>
            <source>Age Ageing</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>45</volume>
            <issue>5</issue>
            <fpage>737</fpage>
            <page-range>737-8</page-range>
            <pub-id pub-id-type="pmid">27220702</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shybut</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>Puckett</surname>
                <given-names>ER</given-names>
              </name>
            </person-group>
            <article-title>Triceps Ruptures After Fluoroquinolone Antibiotics: A Report of 2 Cases.</article-title>
            <source>Sports Health</source>
            <year>2017</year>
            <season>Sep/Oct</season>
            <volume>9</volume>
            <issue>5</issue>
            <fpage>474</fpage>
            <page-range>474-476</page-range>
            <pub-id pub-id-type="pmid">28610536</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morales</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pacurariu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Slattery</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pinheiro</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>McGettigan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kurz</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Association Between Peripheral Neuropathy and Exposure to Oral Fluoroquinolone or Amoxicillin-Clavulanate Therapy.</article-title>
            <source>JAMA Neurol</source>
            <year>2019</year>
            <month>Jul</month>
            <day>01</day>
            <volume>76</volume>
            <issue>7</issue>
            <fpage>827</fpage>
            <page-range>827-833</page-range>
            <pub-id pub-id-type="pmid">31034074</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baggio</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ananda-Rajah</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Fluoroquinolone antibiotics and adverse events.</article-title>
            <source>Aust Prescr</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>44</volume>
            <issue>5</issue>
            <fpage>161</fpage>
            <page-range>161-164</page-range>
            <pub-id pub-id-type="pmid">34728881</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dai</surname>
                <given-names>XC</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>XX</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>HL</given-names>
              </name>
            </person-group>
            <article-title>Relationship between fluoroquinolones and the risk of aortic diseases: a meta-analysis of observational studies.</article-title>
            <source>BMC Cardiovasc Disord</source>
            <year>2020</year>
            <month>Feb</month>
            <day>03</day>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>49</fpage>
            <pub-id pub-id-type="pmid">32013928</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Anaphylaxis to Ciprofloxacin Requiring Emergent Surgical Cricothyrotomy.</article-title>
            <source>Eur J Case Rep Intern Med</source>
            <year>2022</year>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>003180</fpage>
            <pub-id pub-id-type="pmid">35265553</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kelesidis</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fleisher</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tsiodras</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Anaphylactoid reaction considered ciprofloxacin related: a case report and literature review.</article-title>
            <source>Clin Ther</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>32</volume>
            <issue>3</issue>
            <fpage>515</fpage>
            <page-range>515-26</page-range>
            <pub-id pub-id-type="pmid">20399988</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abd-Elsayed</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Elsharkawy</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sakr</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>A severe interaction between Tizanidine and Ciprofloxacin.</article-title>
            <source>J Clin Anesth</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>27</volume>
            <issue>8</issue>
            <fpage>698</fpage>
            <pub-id pub-id-type="pmid">26138629</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Langford</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Diong</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Garber</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Daneman</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Antibiotic Prescribing Choices and Their Comparative C. Difficile Infection Risks: A Longitudinal Case-Cohort Study.</article-title>
            <source>Clin Infect Dis</source>
            <year>2021</year>
            <month>Mar</month>
            <day>01</day>
            <volume>72</volume>
            <issue>5</issue>
            <fpage>836</fpage>
            <page-range>836-844</page-range>
            <pub-id pub-id-type="pmid">32069358</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berhe</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Russom</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bahran</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hagos</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Ciprofloxacin and risk of hypolycemia in non-diabetic patients.</article-title>
            <source>J Med Case Rep</source>
            <year>2019</year>
            <month>May</month>
            <day>12</day>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>142</fpage>
            <pub-id pub-id-type="pmid">31078137</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chou</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Shau</surname>
                <given-names>WY</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Risk of severe dysglycemia among diabetic patients receiving levofloxacin, ciprofloxacin, or moxifloxacin in Taiwan.</article-title>
            <source>Clin Infect Dis</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>57</volume>
            <issue>7</issue>
            <fpage>971</fpage>
            <page-range>971-80</page-range>
            <pub-id pub-id-type="pmid">23948133</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wiseman</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Balfour</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Ciprofloxacin. A review of its pharmacological profile and therapeutic use in the elderly.</article-title>
            <source>Drugs Aging</source>
            <year>1994</year>
            <month>Feb</month>
            <volume>4</volume>
            <issue>2</issue>
            <fpage>145</fpage>
            <page-range>145-73</page-range>
            <pub-id pub-id-type="pmid">8186542</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaplan</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Koren</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Use of ciprofloxacin during breastfeeding.</article-title>
            <source>Can Fam Physician</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>61</volume>
            <issue>4</issue>
            <fpage>343</fpage>
            <page-range>343-4</page-range>
            <pub-id pub-id-type="pmid">26052598</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walden</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Khotimchenko</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hou</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chakravarty</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Varshney</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Effects of Magnesium, Calcium, and Aluminum Chelation on Fluoroquinolone Absorption Rate and Bioavailability: A Computational Study.</article-title>
            <source>Pharmaceutics</source>
            <year>2021</year>
            <month>Apr</month>
            <day>21</day>
            <volume>13</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">33919271</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hajji</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jebali</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mrad</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Blel</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Brahmi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kheder</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Beji</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fatma</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Smaoui</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Krid</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hmida</surname>
                <given-names>FB</given-names>
              </name>
              <name>
                <surname>Rais</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zouaghi</surname>
                <given-names>MK</given-names>
              </name>
            </person-group>
            <article-title>Nephrotoxicity of Ciprofloxacin: Five Cases and a Review of the Literature.</article-title>
            <source>Drug Saf Case Rep</source>
            <year>2018</year>
            <month>Apr</month>
            <day>18</day>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <pub-id pub-id-type="pmid">29671145</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19562.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vaughn</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Gandhi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Conlon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chopra</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Malani</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Flanders</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>The Association of Antibiotic Stewardship With Fluoroquinolone Prescribing in Michigan Hospitals: A Multi-hospital Cohort Study.</article-title>
            <source>Clin Infect Dis</source>
            <year>2019</year>
            <month>Sep</month>
            <day>27</day>
            <volume>69</volume>
            <issue>8</issue>
            <fpage>1269</fpage>
            <page-range>1269-1277</page-range>
            <pub-id pub-id-type="pmid">30759198</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
